PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2007
CASE
AUTH/1994/4/07 Janssen ⭐ Case of the Week

AUTH/1994/4/07: Anonymous v Janssen-Cilag β€” alleged inappropriate hospitality (No breach)

Anonymous alleged pharma-funded conference hospitality (hotel/food/cultural programme). Panel found Janssen-Cilag’s Β£2,000 educational grant and speaker support was acceptable; no evidence it funded…

2007
CASE
AUTH/1982/3/07 Teva

AUTH/1982/3/07: Anonymous v Teva β€” Qvar journal advertisement (no breach)

Anonymous complaint said a Qvar ad in Pulse used partially clothed people and undermined the serious nature of medicines. Panel found the…

2007
CASE
AUTH/1944/1/07 Pfizer

Pfizer: Exubera β€˜maintains long-term glycaemic control’ claim ruled misleading (AUTH/1944/1/07)

DTB criticism triggered a PMCPA case on Pfizer’s Exubera materials claiming β€œmaintains long-term glycaemic control”. Panel found the unqualified long-term claim misleading…

2006
CASE
AUTH/1915/11/06 Novartis Pharmaceuticals UK

AstraZeneca v Novartis: Femara subgroup charts and β€œentire spectrum” press claim found misleading on appeal (AUTH/1915/11/06)

Novartis’ Femara leavepiece implied extra benefit in node-positive/chemo subgroups vs overall trial effect, and a press release claimed licensing across the β€œentire”…

Alliance

Roche v Procter & Gamble and Sanofi-Aventis (Alliance for Better Bone Health): misleading fracture messaging and disparagement of Bonviva

Actonel materials and a sponsored symposium slide were ruled misleading/disparaging about Bonviva (ibandronate). A patient telephone survey was not disguised promotion. Breaches:…

2007
CASE
AUTH/2048/9/07 Grünenthal ⭐ Case of the Week

AUTH/2048/9/07: GrΓΌnenthal – breach of undertaking after old Versatis ad reappeared in Pulse

GrΓΌnenthal voluntarily admitted breaching an undertaking when Pulse re-ran an old Versatis ad previously ruled in breach. Panel found Clause 22 breach;…

2017
CASE
AUTH/2996/12/17 Seqirus

AUTH/2996/12/17: Pharmacist v Seqirus β€” Fluad promotional email and β€˜new guidance’ wording (No breach)

A pharmacist said a Fluad email implied JCVI policy changed for all 65+ and overstated cost-effectiveness. Panel found draft JCVI source was…

2015
CASE
AUTH/2769/5/15 Takeda

Takeda: Clinical trial disclosure (Rienso) β€” no breach, outwith scope (AUTH/2769/5/15)

PMCPA Director’s case on Takeda clinical trial disclosure for Rienso. The matter was found to be outwith the scope of the ABPI…

2018
CASE
AUTH/3025/3/18 Merck Sharp & Dohme

AUTH/3025/3/18: Member of the public v Merck Sharp & Dohme (Nexplanon) – No breach / Outwith scope

Complaint about promotion of Nexplanon. PMCPA concluded no breach and that the matter was outwith the scope of the ABPI Code (2016).…

2006
CASE
AUTH/1863/7/06 Sanofi

AUTH/1863/7/06: Media/Director v Sanofi-Aventis β€” patient organisation meeting trip to Budapest & Paris (No breach)

Observer article criticised Sanofi-Aventis-funded trip for cancer charity leaders/policymakers to Budapest (EACR) and Paris. PMCPA found the programme educational, hospitality proportionate and…

2006
CASE
AUTH/1829/4/06 Allergan ⭐ Case of the Week

Doctor v Allergan (AUTH/1829/4/06): Vistabel POM advert in Aesthetic Medicine – no breach

A doctor alleged a Vistabel (POM) ad appeared in a journal accessible to non-HCPs. The Panel held the publication was aimed at…

2007
CASE
AUTH/2035/8/07 Leo

Leo Pharmaceuticals: Dovobet β€˜Dear Doctor’ letter implied most patients could be switched from Dovonex (AUTH/2035/8/07)

A β€˜Dear Doctor’ letter said Dovobet could replace Dovonex for β€œthe majority” of patients, without clearly explaining key differences (incl. potent steroid…

2007
CASE
AUTH/2015/7/07 Bayer

AUTH/2015/7/07: Lilly v Bayer Schering Pharma – Levitra claims β€˜works first time’ and β€˜many men prefer’ ruled misleading

Lilly challenged Levitra ad/leavepiece claims including β€œWorks first time in 9 out of 10 men”, β€œwine and dine”, and β€œmany men prefer”.…

2019
CASE
Mundibiopharma

Mundibiopharma breached ABPI Code over Invokana virtual booth email: incomplete prescribing information, misleading non-significant outcomes claims, and uncertified linked papers

Invokana virtual booth email/microsite breached the Code for incomplete prescribing info, misleading headline claims implying significance, missing Vokanamet generic name, and failure…

2006
CASE
AUTH/1910/11/06 GlaxoSmithKline

Sanofi Pasteur MSD v GlaxoSmithKline (AUTH/1910/11/06): Cervical cancer disease awareness team ruled to be pre-licence promotion on appeal

GSK’s UK cervical cancer disease awareness field team was initially cleared, but on appeal the cumulative arrangements were ruled to promote an…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training